Solaris Pharma Corporation located in Bridgewater, New Jersey announces final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clobetasol Propionate Cream USP, 0.05% in the following packaging configurations, 15 g, 30 g, 45 g and 60 g tubes. For more updates, please feel free to email us info@solaris-pharma.com
top of page
Search
Recent Posts
See AllSolaris Pharma Corporation is pleased to announce the product approval of Tazarotene Gel, 0.05% and 0.1%.
980
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clindamycin Phosphate Gel USP
2730
bottom of page